USA - engelsk - NLM (National Library of Medicine)

cardinal health - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg in 5 ml - valproic acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precaution (5.1) for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless the drug is essential to the man

USA - engelsk - NLM (National Library of Medicine)

par pharmaceutical - valproic acid (unii: 614oi1z5wi) (valproic acid - unii:614oi1z5wi) - valproic acid 250 mg in 5 ml - valproic acid oral solution is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. valproic acid oral solution is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. complex absence is the term used when other signs are also present. see warnings and precautions (5.1)   for statement regarding fatal hepatic dysfunction. because of the risk to the fetus of decreased iq, neural tube defects, and other major congenital malformations, which may occur very early in pregnancy, valproate should not be administered to a woman of childbearing potential unless th

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

laboratórios basi - indústria farmacêutica, s.a - Ácido zoledrónico - concentrado para solução para perfusão - 4 mg/5 ml - Ácido zoledrónico mono-hidratado 0.8528 mg/ml - zoledronic acid - genérico - duração do tratamento: longa duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

laboratórios basi - indústria farmacêutica, s.a - Ácido zoledrónico - concentrado para solução para perfusão - 4 mg/5 ml - Ácido zoledrónico mono-hidratado 0.8528 mg/ml - zoledronic acid - genérico - duração do tratamento: longa duração

USA - engelsk - NLM (National Library of Medicine)

mylan institutional inc. - mycophenolic acid (unii: hu9dx48n0t) (mycophenolic acid - unii:hu9dx48n0t) - mycophenolic acid 180 mg - mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant. mycophenolic acid delayed-release tablets are indicated for the prophylaxis of organ rejection in pediatric patients 5 years of age and older who are at least 6 months post kidney transplant. mycophenolic acid delayed-release tablets are to be used in combination with cyclosporine and corticosteroids. mycophenolic acid delayed-release tablets and mycophenolate mofetil (mmf) tablets and capsules should not be used interchangeably without physician supervision because the rate of absorption following the administration of these two products is not equivalent. mycophenolic acid delayed-release tablets are contraindicated in patients with a hypersensitivity to mycophenolate sodium, mycophenolic acid (mpa), mycophenolate mofetil, or to any of its excipients. reactions like rash, pruritus, hypotension, and chest pain have been observed in clinical trials and post marketing

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

generis farmacêutica, s.a. - Ácido zoledrónico - concentrado para solução para perfusão - 4 mg/5 ml - Ácido zoledrónico mono-hidratado 0.8528 mg/ml - zoledronic acid - genérico - duração do tratamento: longa duração

Portugal - portugisisk - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

zentiva portugal, lda. - Ácido zoledrónico - solução para perfusão - 5 mg/100 ml - Ácido zoledrónico mono-hidratado 5 mg - zoledronic acid - genérico - duração do tratamento: longa duração

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

biogaran - acide ursodésoxycholique 500 mg - comprimé - 500 mg - pour un comprimé > acide ursodésoxycholique 500 mg - acide biliaire (a appareil digestif et métabolisme) - classe pharmacothérapeutique - code atc : a05aa02.ce médicament contient une substance qui se trouve normalement en petite quantité dans la bile.acide ursodesoxycholique biogaran est utilisé pour : dissoudre les calculs biliaires formés de cholestérol, traiter certaines maladies chroniques du foie.

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

teva bv - acide ursodésoxycholique 500 mg - comprimé - 500 mg - pour un comprimé > acide ursodésoxycholique 500 mg - acide biliaire - classe pharmacothérapeutique acide biliaire (a : appareil digestif et métabolisme) - code atc : a05aa02.ce médicament contient une substance qui se trouve normalement en petite quantité dans la bile.acide ursodesoxycholique teva est utilisé pour : dissoudre les calculs biliaires formés de cholestérol, traiter certaines maladies chroniques du foie.

Frankrike - fransk - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - acide ursodésoxycholique 500 mg - comprimé - 500 mg - pour un comprimé > acide ursodésoxycholique 500 mg - acide biliaire - classe pharmacothérapeutique acide biliaire (a : appareil digestif et métabolisme) - code atc : a05aa02.ce médicament contient une substance qui se trouve normalement en petite quantité dans la bile.acide ursodesoxycholique arrow est utilisé pour : dissoudre les calculs biliaires formés de cholestérol, traiter certaines maladies chroniques du foie.